Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Renal Care

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Acute Therapy

    Organ support and blood purification therapies are essential to improving patient outcomes in the ICU.

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx Therapy

    HDx - also known as expanded hemodialysis - is an innovative therapy that effectively targets the removal of large middle molecules.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration

Learn More
  • "Post-dialysis antiXa higher with HF-HD than with OL-HDF (p=0.024) or HDx (p=0.05)
    At end of dialysis 85% and 72% of the dialyzers in HF-HD and HDx were classified as “clean” whereas only 45% of dialyzers in OL-HDF were classified as “clean”.
    Dose of enoxaparin should be adjusted to the membrane type and size, and dialysis technique should be taken into account"